Literature DB >> 2416553

Interaction of the monoclonal antibodies alpha IR-1 and alpha IR-3 with insulin and somatomedin-C receptors.

S Jacobs, S Cook, M E Svoboda, J J Van Wyk.   

Abstract

alpha IR-3, a monoclonal antibody that interacts with the somatomedin-C receptor, inhibited the binding of somatomedin-C, but not of insulin, to human placental membranes and intact IM-9 cells. alpha IR-1, a monoclonal antibody that interacts with the insulin receptor, did not inhibit the binding of either hormone. Inhibition of somatomedin-C binding by alpha IR-3 was mainly due to a decrease in its affinity. 125I-Labeled alpha IR-3 bound specifically to placental membranes and intact IM-9 cells and was inhibited by concentrations of unlabeled alpha IR-3 that were lower than those required to inhibit somatomedin-C binding. [125I]alpha IR-3 binding was also inhibited by somatomedin-C and insulin, but only at very high concentrations. A410, a rabbit antiserum that reacts with both receptors for insulin and somatomedin-C, also inhibited labeled alpha IR-3 binding. alpha IR-I did not. These results help to define the epitopes with which these antibodies interact.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416553     DOI: 10.1210/endo-118-1-223

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

2.  High affinity binding sites for proinsulin in human IM-9 lymphoblasts.

Authors:  P M Jehle; M P Lutz; R D Fussgaenger
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

3.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

4.  Insulin receptor is phosphorylated in response to treatment of HepG2 cells with insulin-like growth factor I.

Authors:  V Duronio
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

5.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.

Authors:  C L Arteaga; L J Kitten; E B Coronado; S Jacobs; F C Kull; D C Allred; C K Osborne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

Review 6.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines.

Authors:  M Rotsch; M Maasberg; C Erbil; G Jaques; U Worsch; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone.

Authors:  J M Siegfried; P G Kasprzyk; A M Treston; J L Mulshine; K A Quinn; F Cuttitta
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 9.  Interference of the IGF system as a strategy to inhibit breast cancer growth.

Authors:  C L Arteaga
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 10.  Type 1 IGF receptor in human breast diseases.

Authors:  J P Peyrat; J Bonneterre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.